Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
Zacks Investment Research on MSN
CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...
Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...
GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...
Bynes has been vocal about her weight-loss journey, which began in June with the trendy GLP-1 agonist drug Ozempic so she ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback